Sponsored by
We are very excited to see this news about GB13! The Musella Foundation helped get initial research for this therapy started more than a decade ago, with grant funding provided in 2010 and 2012. Now, the company behind GB13, Targepeutics, is collaborating with Penn State College of Medicine, the Beat Childhood Cancer Research Consortium, and Four Diamonds to complete the final preclinical work needed to submit an FDA application and begin a Phase I/II clinical trial for children with DIPG.
GB13 is an investigational immunotoxin that uses a precision-targeting approach to attack tumor cells expressing IL13Ra2, a receptor commonly found on brain tumors but rarely on normal brain tissue. The preclinical evidence supporting GB13 is very strong, and the therapy received Rare Pediatric Disease Designation (RPDD) from the FDA last year. We hope to see this therapy advance to trial soon.